20:07 , Jul 25, 2018 |  BC Extra  |  Company News

Management Tracks: Albireo, ObsEva

Pediatric liver disease company Albireo Pharma Inc. (NASDAQ:ALBO) said CMO Paresh Soni will step down. He is succeeded by Patrick Horn, who was SVP of medical and clinical development at Orphan Technologies Ltd. (Rapperswil, Switzerland). Reproductive...
22:00 , Jun 18, 2018 |  BC Extra  |  Company News

Management tracks: Ionis, Albireo

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) hired Damien McDevitt as CBO. He was SVP of corporate development at Acadia Pharmaceuticals Inc. (NASDAQ:ACAD). Hepatic disease company Albireo Pharma Inc. (NASDAQ:ALBO) hired Jason Duncan as general counsel. He was general...
23:09 , Apr 6, 2018 |  BioCentury  |  Finance

Fundamentally driven

Continued struggles by the mega-cap bellwethers and the resurgence of volatility in global equity markets were the major themes of 1Q18, whipsawing biotech stocks throughout the quarter but leaving index values little changed on the...
19:46 , Jan 26, 2018 |  BC Week In Review  |  Financial News

GI and hepatic company Albireo raises $65M follow-on

On Jan. 25, gastrointestinal and hepatic company Albireo Pharma Inc. (NASDAQ:ALBO) raised $65 million after selling 2 million shares at $33 in a follow-on underwritten by Cowen, William Blair, Needham, Wedbush PacGrow and Roth. The...
23:03 , Jan 25, 2018 |  BC Extra  |  Financial News

Follow-on roundup: Audentes, Iovance

At least six companies have priced follow-ons since Wednesday’s market close, raising more than $600 million. Gene therapy company Audentes Therapeutics Inc. (NASDAQ:BOLD) raised $201.3 million after hours on Wednesday through the sale of 5.8...
19:36 , Jan 19, 2018 |  BC Week In Review  |  Clinical News

Albireo gets $55M for elobixibat approval in Japan

Albireo Pharma Inc. (NASDAQ:ALBO) nearly doubled its cash reserves after Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Goofice elobixibat to treat chronic constipation. The approval triggered about $55 million in payments to the...
16:26 , Jan 19, 2018 |  BC Extra  |  Company News

Albireo receives $55M for elobixibat approval in Japan

Albireo Pharma Inc. (NASDAQ:ALBO) nearly doubled its cash reserves after Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Goofice elobixibat on Friday to treat chronic constipation. The approval triggered about $55 million in payments...
18:24 , Jan 12, 2018 |  BC Week In Review  |  Company News

Albireo in elobixibat royalty deal with HealthCare Royalty

HealthCare Royalty Partners (Stamford, Conn.) entered into a deal with the Elobix AB subsidiary of Albireo Pharma Inc. (NASDAQ:ALBO). In exchange for royalties and milestones related to elobixibat and payable by the EA Pharma Co....
22:46 , Jan 8, 2018 |  BC Extra  |  Company News

HealthCare Royalty in deals with Agenus, Albireo

Agenus Inc. (NASDAQ:AGEN) said it will sell to HealthCare Royalty Partners (Stamford, Conn.) royalty rights on sales of vaccines from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) containing Agenus' QS-21 Stimulon adjuvant. The biotech will receive $190 million...
18:37 , Nov 17, 2017 |  BC Week In Review  |  Clinical News

Albireo reports Phase II data for A4250 in cholestatic liver disease

Albireo Pharma Inc. (NASDAQ:ALBO) said A4250 was well tolerated and led to no treatment-related serious adverse events in a Phase II trial in 20 patients ages 1-17 with cholestatic liver disease, including progressive familial intrahepatic...